Online inquiry

IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10344MR)

This product GTTS-WQ10344MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IL17A&TNFSF13B gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002190.3; NM_001145645.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3605; 10673
UniProt ID Q16552; Q9Y275
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ10344MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3259MR IVTScrip™ mRNA-Anti-TNF, ART621(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ART621
GTTS-WQ13646MR IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RB4v1.2
GTTS-WQ13771MR IVTScrip™ mRNA-Anti-MSTN, REGN-1033(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN-1033
GTTS-WQ8020MR IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA GZ-402668
GTTS-WQ2311MR IVTScrip™ mRNA-Anti-C5, ALXN-1210(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ALXN-1210
GTTS-WQ5219MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CB 2679d
GTTS-WQ1283MR IVTScrip™ mRNA-Anti-RGMA, ABT-555(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABT-555
GTTS-WQ15979MR IVTScrip™ mRNA-Anti-Felcat IL31, ZTS-00521505(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ZTS-00521505
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW